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Clinical Relevance*Scientific rationale for the study*: Published meta‐analyses on SnF~2~ dentifrices typically exclude shorter‐term studies and include a variety of different SnF~2~ formulations, which can vary in bioavailable levels of SnF~2~ and performance. This meta‐analysis examined shorter‐term gingival health effects of a bioavailable gluconate chelated 0.454% SnF~2~ family of dentifrices.*Principal findings*: In gingivitis studies assessing a bioavailable gluconate chelated SnF~2~ paste versus a negative or positive control, the SnF~2~ paste significantly reduced the number of bleeding sites.*Practical implications*: Bioavailable gluconate chelated SnF~2~ dentifrices consistently reduced gingival bleeding across the spectrum of gingivitis levels, regardless of baseline level of disease.

1. INTRODUCTION {#jcpe13203-sec-0006}
===============

Periodontal diseases are a group of chronic inflammatory diseases of the gingiva and periodontium that have a high global prevalence and are a primary aetiology of tooth loss (Kassebaum et al., [2014](#jcpe13203-bib-0034){ref-type="ref"}; Marcenes et al., [2013](#jcpe13203-bib-0042){ref-type="ref"}). Periodontal disease initially presents as gingivitis, a plaque‐induced inflammation of the marginal and attached gingiva (Page, [1986](#jcpe13203-bib-0048){ref-type="ref"}). The clinical symptoms of gingivitis include redness, oedema and bleeding at the gingival margin. The high prevalence of gingivitis in adult populations has been established, with multiple global studies estimating the prevalence to be 75% or higher (Beaglehole et al., [2009](#jcpe13203-bib-0007){ref-type="ref"}; Hugoson & Jordon, [1982](#jcpe13203-bib-0033){ref-type="ref"}). Treatment and management of gingivitis is of clinical importance, because left untreated it can progress to periodontitis which includes loss of clinical attachment, recession, increased tooth mobility and in some events tooth loss. The absence of bleeding on probing over repetitive dental examinations has been shown to be a reliable predictor for the maintenance of periodontal health, as measured by lack of attachment loss, in patients following active periodontal therapy (Lang, Adler, Joss, & Nyman, [1990](#jcpe13203-bib-0035){ref-type="ref"}).

The microbial aetiology of gingivitis was clearly established by Löe, Theliade, and Jensen, through his seminal research on induced gingivitis through the cessation of daily oral hygiene (Löe et al., [1965](#jcpe13203-bib-0037){ref-type="ref"}). This experiment established that gingivitis could be initiated through plaque biofilm development and maturation, and then reversed by removal of the plaque biofilm. In the ensuing 50 years, researchers have elucidated the underlying microbial and host pathways that are operative in the initiation, propagation and reversal of gingivitis. Loesch and Syed ([1978](#jcpe13203-bib-0038){ref-type="ref"}) reported on the microbial succession that occurred in the plaque biofilm during the experimental gingivitis phase, with a shift from a *Streptococcus* dominated biofilm to an *Actinomyces* biofilm as the biofilm aged over the 3‐week period of no oral hygiene (Loesch & Syed, [1978](#jcpe13203-bib-0038){ref-type="ref"}; Syed & Loesche, [1978](#jcpe13203-bib-0061){ref-type="ref"}). Importantly, the bacterial species *Actinomyces viscosus* and *Bacteroides melaninogenicus* were increased significantly at gingival sites that bled, establishing an association (Loesch & Syed, [1978](#jcpe13203-bib-0038){ref-type="ref"}). More recently, *Actinomyces viscosus* and *Prevotella intermedia* were found in overabundance (*p* \< .05) in twins at sites that were not flossed relative to the companion twin at sites that were flossed over a two‐week treatment period (Corby et al., [2008](#jcpe13203-bib-0013){ref-type="ref"}). The flossing treatment group had \~40% reductions in gingival bleeding versus the non‐flossing treatment group, supporting the association of specific bacteria to gingival bleeding in chronic gingivitis (Biesbrock et al., [2006](#jcpe13203-bib-0010){ref-type="ref"}). Inflammation is induced by specific activity of the microbial biofilm that includes the production of a number of bacterial virulence factors ("toxins") that are capable of triggering an immune inflammatory response, including lipopolysaccharide, lipoteichoic acid, short chain fatty acids, collagenase and elastase enzymes (gingipain) (Ginsburg, [2002](#jcpe13203-bib-0018){ref-type="ref"}; Hamada, Takada, Ogawa, Fujiwara, & Mihara, [1990](#jcpe13203-bib-0022){ref-type="ref"}; Holt & Bramanti, [1991](#jcpe13203-bib-0031){ref-type="ref"}; Madianos, Bobetis, & Kinane, [2005](#jcpe13203-bib-0039){ref-type="ref"}). These microbial virulence factors can interact with host epithelial and immune cells through specialized cell receptors, such as toll receptors, that mediate the initiation of the host inflammatory cascade (Beutler et al., [2006](#jcpe13203-bib-0009){ref-type="ref"}; Hans & Hans, [2011](#jcpe13203-bib-0023){ref-type="ref"}; Takeda & Akira, [2005](#jcpe13203-bib-0062){ref-type="ref"}).

Treatment and management of gingivitis is predicated on direct removal of plaque or suppression of plaque biofilm and its metabolites. Historically, the primary treatment modality to physically disrupt and remove plaque biofilm has been daily oral hygiene, primarily toothbrushing and flossing. Lang et al. established a minimal brushing frequency of once every 48 hr as a necessity to suppress the initiation and progression of gingivitis (Lang, Cumming, & Löe, [1973](#jcpe13203-bib-0036){ref-type="ref"}). Routine dental prophylaxis is also used as a treatment in the management of gingivitis. Two separate cohorts report median reductions in gingival bleeding of 40% and 66%, respectively (McClanahan, Bartizek, & Biesbrock, [2001](#jcpe13203-bib-0044){ref-type="ref"}), one week following dental prophylaxis. Several antimicrobial chemotherapeutic dentifrices and mouthrinses have been clinically proven for the treatment and management of gingivitis, including stannous fluoride (SnF~2~), triclosan, essential oils, cetylpyridinium chloride and chlorhexidine. These actives have all been shown to have direct bactericidal mechanisms through which they reduce gingival inflammation.

A number of meta‐analyses examining the effects of SnF~2~ dentifrices on plaque and gingivitis have been reported in the past fifteen years (Gunsolley, [2006](#jcpe13203-bib-0021){ref-type="ref"}; Paraskevas & van der Weijden, [2006](#jcpe13203-bib-0049){ref-type="ref"}; Sälzer, Slot, Dörfer, & van der Weijden, [2015](#jcpe13203-bib-0053){ref-type="ref"}). All of these meta‐analyses confirm the ability of SnF~2~ dentifrices to reduce gingivitis and gingival bleeding. Importantly, these meta‐analyses were limited to studies of at least 6 months in duration, which led to the exclusion of a number of shorter‐term gingivitis studies. The SnF~2~ dentifrices included in these meta‐analyses varied in formulation composition, which may introduce differences in the amount of bioavailable SnF~2~ across formulations. Formulation composition is critically important to maintaining bioavailable SnF~2~ concentrations in the dentifrice over time, which in turn affects antimicrobial and antigingivitis efficacy (Tinannoff, [1995](#jcpe13203-bib-0063){ref-type="ref"}; White, [1995](#jcpe13203-bib-0066){ref-type="ref"}). The meta‐analysis reported in this paper was explicitly designed to include earlier timepoints (2 to 12 weeks) in randomized clinical trials (RCTs), as a preponderance of the clinical evidence exists in the form of shorter duration gingivitis studies. We used the PICO model: Patient: adult gingivitis sufferer; Intervention: family of 0.454% bioavailable gluconate chelated SnF~2~ dentifrices from a single manufacturer (The Procter & Gamble Company); Comparator: positive or negative control; Outcome: number of bleeding sites derived from the Löe--Silness Gingival Index (LSGI) or Gingival Bleeding Index (GBI). The objective was to estimate gingivitis effects of a bioavailable gluconate chelated 0.454% SnF~2~ family of dentifrices in adult subjects versus positive (triclosan) and negative (NaF or MFP) controls when used for 3 months or less (PICO question). The primary rationale for examining bioavailable SnF~2~ dentifrice from a single manufacturer was to ensure products had bioavailable levels of SnF~2~ through access to both analytical and antimicrobial performance data. Secondarily, it was important to have access to subject‐level data from each RCT to facilitate transition analyses.

2. MATERIALS AND METHODS {#jcpe13203-sec-0007}
========================

The meta‐analysis was conducted in accordance with the general principles of the PRISMA statement (Moher, Liberati, Tetzlaff, Altman, & The PRISMA Group, [2009](#jcpe13203-bib-0045){ref-type="ref"}).

2.1. Search {#jcpe13203-sec-0008}
-----------

A search limited to the Procter & Gamble Oral Care Clinical archive was undertaken to identify relevant studies with results available as of March 2018 for inclusion in this meta‐analysis.

2.2. Eligibility criteria {#jcpe13203-sec-0009}
-------------------------

We included data from evaluations at 3 months or less from parallel randomized, blinded, controlled clinical trials that had intervention and control groups in human subjects and reported the effect of a family of 0.454% bioavailable SnF~2~ dentifrices on gingivitis outcomes.

2.3. Study selection and data collection {#jcpe13203-sec-0010}
----------------------------------------

Two authors (TH and YZ) independently assessed the eligibility of all studies retrieved from the archives. Disagreements between the evaluators concerning the selected studies were resolved by discussion. From the studies included in the final analysis, we extracted the following data: study name and year; country; study design; participants; age and gender; intervention; follow‐up period; oral health condition; and values of outcome measurements (subject‐level data, sample size, means and standard deviations) in both intervention and control groups. If the study had more than one follow‐up visit, we used the assessment up to and including the 3‐month visit for data extraction.

2.4. Risk of bias assessment {#jcpe13203-sec-0011}
----------------------------

We assessed the quality of the included individual studies based on the revised Cochrane collaboration tool for assessing the risk of bias (Sterne et al., [2019](#jcpe13203-bib-0060){ref-type="ref"}).

2.5. Statistical analysis {#jcpe13203-sec-0012}
-------------------------

For the gingivitis (bleeding sites derived from LSGI or GBI) efficacy variable, the generic inverse variance method with both fixed and random effects models was used to calculate the summary differences between the SnF~2~ dentifrice and the control. If there were four or more studies to be analysed, the "random effects" model was chosen to calculate the weighted average of the treatment effects across the studies (Higgins & Green, [2009](#jcpe13203-bib-0030){ref-type="ref"}). If there were fewer than four studies, the "fixed effects" model was used (Poklepovic et al., [2012](#jcpe13203-bib-0051){ref-type="ref"}). Results included gingivitis assessments up to 12 weeks. For studies with multiple interventions or controls, the weighted average of the scores and pooled standard deviation was calculated to obtain a single pairwise comparison and to mitigate the unit‐of‐analysis error.

The estimated mean differences and the 95% confidence intervals (CIs) are presented in forest plots. Tests for overall effects were based on z‐statistics and associated p values. Percent change from control was calculated by the weighted percent change from the control from different studies where the weights were calculated from the random or fixed effects model. Additionally, a subgroup analysis was performed using mean bleeding site data. The study subgroups were defined using the study‐level baseline mean bleeding scores as follows: mild (\<17 bleeding sites), moderate (17--50 bleeding sites) or severe (\>50 bleeding sites).

The current Gingivitis Case Definition from the 2017 World Workshop in Periodontology (Trombelli, Farina, Silva, & Tatakis, [2018](#jcpe13203-bib-0064){ref-type="ref"}) was used to classify subject‐level gingival bleeding at baseline and the final visit used in the analysis as: generally healthy (\<10% bleeding sites), localized gingivitis (10%--30% bleeding sites) or generalized gingivitis (\>30% bleeding sites). Transition rates by treatment were then calculated and used to generate odds ratios with 95% confidence intervals.

All summary‐level meta‐analyses were conducted using the "metafor" package in R version 3.2.3 (R Development Core Team, [2015](#jcpe13203-bib-0052){ref-type="ref"}; Viechtbauer, [2010](#jcpe13203-bib-0065){ref-type="ref"}). All subject‐level analyses were conducted using SAS 9.4 (SAS Institute).

3. RESULTS {#jcpe13203-sec-0013}
==========

Eighteen RCTs with 2,890 subjects across three countries assessed gingivitis health benefits. In 12 gingivitis studies assessing a SnF~2~ dentifrice versus a negative control (NaF and MFP), a change in the average number of bleeding sites of −16.3 (95% CI: −27.8, −4.9) was observed equating to a 51% benefit versus the negative control (*p* \< .001). (Figure [1](#jcpe13203-fig-0001){ref-type="fig"}a) In 7 gingivitis studies assessing a SnF~2~‐containing dentifrice versus a positive control (triclosan), a change in the average number of bleeding sites of −3.6 (95% CI: −5.4, −1.8) was observed equating to a 31% benefit versus the positive control (*p* \< .001). (Figure [1](#jcpe13203-fig-0001){ref-type="fig"}b).

![Results from RCTs included in the bleeding site meta‐analyses: SnF~2~ dentifrice versus a negative control (a) and positive control (b)](JCPE-46-1205-g001){#jcpe13203-fig-0001}

Further analysis of the effect of baseline gingivitis status was assessed at both the mean and subject levels. The changes (95% CI) in the average number of bleeding sites were −6.1 (−9.5, −2.7), −5.3 (−7.6, −2.9) and −49.8 (−53.2, −46.4) for studies in the mild, moderate and severe groups compared to the negative control. (Figure [1](#jcpe13203-fig-0001){ref-type="fig"}a). These reductions equate to a 59%, 35% and 67% benefit versus the negative control, respectively (*p* \< .001). Study subgroup analysis showed a change (95% CI) in the average number of bleeding sites of −3.0 (−3.7, −2.3) and −2.4 (−2.8, −1.9) for mild and moderate groups compared to the positive control. (Figure [1](#jcpe13203-fig-0001){ref-type="fig"}b) These reductions equate to a 33% and 20% benefit versus the positive control, respectively (*p* \< .001).

The subjects receiving the SnF~2~ dentifrice had a greater response than positive and negative controls at every percentile of the percent change from baseline bleeding response distribution (Figure [2](#jcpe13203-fig-0002){ref-type="fig"}a,b).

![Gingival bleeding response versus baseline bleeding levels: SnF2 dentifrice versus a negative control (a) and positive control (b)](JCPE-46-1205-g002){#jcpe13203-fig-0002}

Additionally, at the subject level, the SnF~2~ dentifrice benefit on gingival bleeding response relative to the negative and positive control was observed across the entire range of baseline bleeding. (Figure [3](#jcpe13203-fig-0003){ref-type="fig"}a,b).

![Distribution of percent change from baseline in the number of bleeding sites: SnF~2~ dentifrice versus a negative control (a) and positive control (b)](JCPE-46-1205-g003){#jcpe13203-fig-0003}

In negative‐controlled studies, of the 444 subjects in the SnF~2~ treatment group with localized or generalized gingivitis at baseline, 301 (68%) transitioned to generally healthy while only 139 (36%) of the 386 subjects in the negative control transitioned to generally healthy. (Table [1](#jcpe13203-tbl-0001){ref-type="table"}a) That is, subjects with localized or generalized gingivitis had 3.7 times better odds (95% CI \[2.8, 5.0\]) of shifting to generally healthy using SnF~2~ versus a negative control. In positive‐controlled studies, of the 348 subjects in the SnF~2~ treatment group with localized or generalized gingivitis at baseline, 246 (71%) transitioned to generally healthy while only 152 (46%) of the 331 subjects in the positive control transitioned to generally healthy. (Table [1](#jcpe13203-tbl-0001){ref-type="table"}b) That is, subjects with localized or generalized gingivitis had 2.8 times better odds (95% CI \[2.1, 3.9\]) of shifting to generally healthy using SnF~2~ versus a positive control.

###### 

Baseline and post‐baseline % bleeding sites in (a) negative‐controlled studies; (b) positive‐controlled studies

  Treatment     Baseline   Total       Post‐baseline   
  ------------- ---------- ----------- --------------- ---------
  \(a\)                                                
  SnF~2~        \<10%      436         430 (99%)       6 (1%)
  ≥10%          444        301 (68%)   143 (32%)       
  Neg Control   \<10%      365         332 (91%)       33 (9%)
  ≥10%          386        139 (36%)   247 (64%)       
  \(b\)                                                
  SnF~2~        \<10%      400         397 (99%)       3 (1%)
  ≥10%          348        246 (71%)   102 (29%)       
  Pos Control   \<10%      363         354 (98%)       9 (2%)
  ≥10%          331        152 (46%)   179 (54%)       

\(a\) Subjects with localized or generalized gingivitis had 3.7 times better odds (95% CI \[2.8, 5.0\]) of shifting to generally healthy (\<10% bleeding) using SnF~2~ versus a negative control.

\(b\) Subjects with localized or generalized gingivitis had 2.8 times better odds (95% CI \[2.1, 3.9\]) of shifting to generally healthy (\<10% bleeding) using SnF~2~ versus a positive control.
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3.1. Risk of bias {#jcpe13203-sec-0014}
-----------------

The risk of bias in individual studies was deemed to be low in all categories of bias (Figure [S1](#jcpe13203-sup-0002){ref-type="supplementary-material"}, File [S1](#jcpe13203-sup-0001){ref-type="supplementary-material"}). All studies included in the meta‐analysis were randomized and blinded with the allocation sequence concealed until all participants were enrolled and assigned to treatment (bias arising from the randomization process). The individual study analyses were based on the per‐protocol population to assess the effect of adhering to intervention, and examiners were not aware of a participants' assigned intervention during the trial (bias due to deviations from the intended interventions). Outcome data were available for all or nearly all subjects (bias due to missing outcome data). Valid and reliable outcome measures were used in all studies, and in the case of single‐blind studies, the examiners were not aware of the participants' assigned intervention during the trial (bias in measurement of the outcome). All published and unpublished studies had a pre‐specified analysis plan, and results were included regardless of outcome (bias in the selection of the reported result).

All of the studies included in this meta‐analysis were sponsored by The Procter & Gamble Company, which is a potential source of systematic bias. However, this across‐study risk of bias is mitigated to a large degree in that all studies were randomized, blinded and controlled and by the robust nature and scope of the research involving 18 studies across 7 sites in 3 different countries, which support the results are valid and reproducible.

4. DISCUSSION {#jcpe13203-sec-0015}
=============

The results of this meta‐analysis provide further evidence that bioavailable gluconate chelated 0.454% SnF~2~ dentifrices deliver significantly greater reductions in gingivitis as measured by gingival bleeding than negative control (NaF or MFP) dentifrices. The Paraskevas and van der Weijden ([2006](#jcpe13203-bib-0049){ref-type="ref"}) meta‐analysis confirmed that SnF~2~ dentifrices provide statistically significant reductions in gingivitis versus sodium fluoride negative control dentifrices. The Gunsolley ([2006](#jcpe13203-bib-0021){ref-type="ref"}) meta‐analysis similarly found that SnF~2~ provides statistically significant gingivitis reductions versus sodium fluoride negative control dentifrices. More recently, the Sälzer et al. ([2015](#jcpe13203-bib-0053){ref-type="ref"}) meta‐analysis compared the gingivitis effects of SnF~2~ and triclosan dentifrices (Sälzer et al., [2015](#jcpe13203-bib-0053){ref-type="ref"}). SnF~2~ dentifrices statistically significantly reduced gingival bleeding scores relative to triclosan‐containing dentifrices, with no statistically significant difference observed in gingivitis scores between the two treatments. In this study, the meta‐analysis results from 18 studies in 2,890 subjects demonstrated a 51% reduction and a 31% reduction in gingival bleeding for SnF~2~ dentifrices versus negative control and positive control dentifrices, respectively. The results were observed over a 2‐ to 12‐week treatment period and are generally consistent with results observed at 6 months in individual RCTs (Archila et al., [2005](#jcpe13203-bib-0004){ref-type="ref"}; Mallatt et al., [2007](#jcpe13203-bib-0040){ref-type="ref"}; Mankodi et al., [2005](#jcpe13203-bib-0041){ref-type="ref"}). Furthermore, the observed results are generally consistent with results reported in previous meta‐analyses of 6‐month studies (Gunsolley, [2006](#jcpe13203-bib-0021){ref-type="ref"}; Paraskevas & van der Weijden, [2006](#jcpe13203-bib-0049){ref-type="ref"}; Sälzer et al., [2015](#jcpe13203-bib-0053){ref-type="ref"}). The majority of the dentifrices in these previously published meta‐analyses contained 0.454% SnF~2~ products with gluconate chelant systems, although they also included SnF~2~ products without gluconate chelant systems.

There are four publications in the peer‐reviewed published literature evaluating gingivitis effects of gluconate chelated SnF~2~ dentifrices that were not included in this meta‐analysis because they did not meet a key criterion of access to subject‐level data (Ayad, Stewart, Zhang, & Proskin, [2010](#jcpe13203-bib-0005){ref-type="ref"}; Boneta et al., [2010](#jcpe13203-bib-0011){ref-type="ref"}; Seriwatanachai et al., [2019](#jcpe13203-bib-0056){ref-type="ref"}; Singh et al., [2010](#jcpe13203-bib-0059){ref-type="ref"}). All four studies were sponsored by a single manufacturer (Colgate‐Palmolive). Three RCTs compared the SnF~2~ dentifrice to triclosan dentifrice (Colgate Total) over periods of 6 weeks to 6 months. Two of the studies also included a negative control. These studies reported that the triclosan dentifrice produced statistically significantly greater improvements in gingival health compared to the SnF~2~ dentifrice and the SnF~2~ dentifrice produced statistically significantly greater improvements in gingival health compared to the negative control. Importantly, the only two global manufacturers to market triclosan dentifrices (Procter & Gamble and Colgate‐Palmolive) chose to discontinue triclosan dentifrice in favour of stannous fluoride formulations. The most recent study by Seriwatanachai et al. evaluated two SnF~2~ dentifrices, including gluconate chelated dentifrice and a novel formulation with zinc phosphate. Both SnF~2~ dentifrices improved gingival health statistically significantly better than the negative control with no statistically significant differences between the SnF~2~ dentifrices.

Two other recent studies assessing SnF~2~ with zinc phosphate and SnF~2~ with tripolyphosphate dentifrices, not gluconate chelant systems, demonstrated that they deliver reductions in gingivitis and gingival bleeding relative to negative control dentifrice at both 3 and 6 months (Hu et al., [2019](#jcpe13203-bib-0032){ref-type="ref"}; Parkinson, Amini, Wu, & Gallob, [2018](#jcpe13203-bib-0050){ref-type="ref"}). Taken collectively, numerous 0.454% SnF~2~ dentifrices have been reported to provide reductions in gingival inflammation and bleeding. One limitation of this current meta‐analysis is that it cannot address potential differences in the clinical efficacy of varying 0.454% SnF~2~ dentifrice formulations, which will require more comparative testing in randomized clinical trials.

At the recent 2017 World Workshop of Periodontology, new guidelines were proposed that define generalized gingivitis cases and localized gingivitis cases (Trombelli et al., [2018](#jcpe13203-bib-0064){ref-type="ref"}). Furthermore, patients with \< 10% bleeding sites, without attachment loss and radiographic bone loss, are considered clinically periodontally healthy, albeit with localized sites of gingival inflammation. The relative baseline gingivitis level of the patients in the studies included in this meta‐analysis spanned a large distribution of the disease ranging from generally periodontally healthy with localized gingival inflammation sites to generalized gingivitis cases, with baseline bleeding sites per subject ranging from 0 to 147 bleeding sites. Importantly, SnF~2~ dentifrices provided reductions in gingivitis across the entire baseline disease spectrum, including generalized gingivitis case types, localized gingivitis case types and generally periodontally healthy case types with isolated sites of gingival inflammation (Figure [3](#jcpe13203-fig-0003){ref-type="fig"}a,b). The mean percent reduction in bleeding sites in studies classified as mild, moderate and severe was 59%, 35% and 67%, respectively. These represent large meaningful reductions in gingival bleeding, which are similar in magnitude to the 40%--66% delivered one week following a dental prophylaxis (McClanahan et al., [2001](#jcpe13203-bib-0044){ref-type="ref"}). The magnitude of reduction in bleeding provided by SnF~2~ dentifrices is also similar to that observed with flossing treatment, which delivers \~40% reductions in gingival bleeding versus non‐flossing treatment (Biesbrock et al., [2006](#jcpe13203-bib-0010){ref-type="ref"}).

At every percentile of the percent change from baseline bleeding response distribution, SnF~2~ had a greater response than positive and negative controls (Figure [2](#jcpe13203-fig-0002){ref-type="fig"}a,b). For negative control studies, half of the SnF~2~ subjects had a 67% reduction from baseline compared to half of the negative control subjects who had a 28% reduction. For positive control studies, half of the SnF~2~ subjects had a 60% reduction from baseline compared to half of the positive control subjects had a 38% reduction. Importantly, results from the subject‐level analyses support that subjects using a SnF~2~ dentifrice had 3.7 times better odds of transitioning from localized or generalized gingivitis to generally healthy relative to those using the negative control and 2.8 times better odds of transitioning to generally healthy relative to those using the positive control (Table [1](#jcpe13203-tbl-0001){ref-type="table"}).

Gingival bleeding is an objective measure of inflammation that has been positively correlated to histologic changes in the gingiva, which include a greater percentage of cell‐rich collagen‐poor connective tissue consistent with an inflammatory infiltrate, as compared to non‐bleeding sites (Greenstein, Caton, & Polson, [1981](#jcpe13203-bib-0020){ref-type="ref"}). The clinical significance of gingival bleeding should not be underestimated, as chronic inflammation of the gingiva and periodontium has been shown to be a significant risk factor for both periodontal attachment loss and recession. Sites with persistent gingival bleeding over multiple periodic examinations have been shown to have higher odds for progressive attachment loss compared to non‐bleeding sites (Schatzle et al., [2003](#jcpe13203-bib-0054){ref-type="ref"}). Over a 26‐year observation period in a population of well‐maintained, well‐educated men who practiced regular oral hygiene, sites that bled consistently throughout the course of the study had approximately 70% more attachment loss than sites that were consistently non‐inflamed, yielding an odds ratio of 3.22 for inflamed sites (bleeding) converting to attachment loss (Schatzle et al., [2003](#jcpe13203-bib-0054){ref-type="ref"}). These persistent bleeding sites can exist even if patients are considered generally healthy. In addition, the absence of persistent gingival bleeding on probing has also been shown to have a high negative predictive value of 98.1% for disease progression, as measured by ≥2 mm attachment loss, in a periodontal maintenance population over a 2.5‐year observation period (Lang et al., [1990](#jcpe13203-bib-0035){ref-type="ref"}). It should be noted that bleeding on probing and gingival bleeding upon sweeping may not represent the same inflammatory lesion in deeper pockets (≥5 mm); however in shallower pocket depths (≤3 mm), it is likely that these clinical measures significantly overlap. The established relationship between persistent gingival bleeding and attachment loss is the mechanistic basis for gingival inflammation as a risk factor for tooth mortality. Importantly, teeth surrounded by persistent inflamed gingival tissue (presence of bleeding) had a 46‐fold higher risk of being lost over a 26‐year observation period, compared to teeth surrounded by inflammation‐free gingival tissues (absence of bleeding) (Schatzle et al., [2004](#jcpe13203-bib-0055){ref-type="ref"}).

Results of this meta‐analysis quantify the gingivitis effects of a bioavailable gluconate chelated 0.454% SnF~2~ family of dentifrices in adult subjects versus positive (triclosan) and negative (NaF or MFP) controls when used for 3 months or less and add further supporting evidence of clinically meaningful benefits. The generalizability of these studies is limited to the bioavailable gluconate chelated SnF~2~ formulas examined in this report.

CONFLICT OF INTEREST {#jcpe13203-sec-0017}
====================

The roles of the study sponsor (P&G) and clinical sites were consistent across all studies. The study sponsor was responsible for investigator and site identification and monitoring and statistical analyses. The independent clinical sites were responsible for IRB submission, recruitment and study conduct. Protocol development and study interpretation were jointly performed by the investigator and sponsor.
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The protocol for this meta‐analysis has been registered in clinicaltrials.gov (NCT03970759).

STUDIES IN FIGURE [1](#jcpe13203-fig-0001){ref-type="fig"}A. {#jcpe13203-sec-0018}
============================================================

Study referenceFormulaYear Study initiatedLocationMeasures & inclusion criteriaControlLength of measurement*N*FemaleMean age in years (*SD*)Nachnani et al., [2019](#jcpe13203-bib-0046){ref-type="ref"}, Summary [S2](#jcpe13203-sup-0001){ref-type="supplementary-material"}0.45% SnF~2~ 0.51% SnCl~2~ 0.53% Zn citrate2018California, USABleeding sitesBS: ≥20Negative, SMFP12 weeks8469%38.7 (15.62)Nachnani, Lee, Gurich, Zou, & Anastasia, [2018](#jcpe13203-bib-0047){ref-type="ref"}, Summary [S3](#jcpe13203-sup-0001){ref-type="supplementary-material"}0.45% SnF~2~ 2.5% Zn lactate2017California, USABleeding sites LSGIBS: ≥20Negative, SMFP4 weeks4959%42.2 (15.26)Amini, Miner, & Gerlach, [2016](#jcpe13203-bib-0003){ref-type="ref"}, Summary [S4](#jcpe13203-sup-0001){ref-type="supplementary-material"}0.45% SnF2 2.5% Zn lactate2015Nevada, USABleeding sitesBS: n/aNegative, NaF2 weeks7057%36.1 (11.53)Amini, Amini, & Gerlach, [2018](#jcpe13203-bib-0001){ref-type="ref"}0.45% SnF~2~ 2.5% Zn lactate2013Nevada, USABleeding sites MGIBS: ≥15Negative, SMFP3 weeks6157%33.4 (11.95)Goyal, Qaqish, He, Anastasia, & Winston, [2017](#jcpe13203-bib-0019){ref-type="ref"}, Summary [S5](#jcpe13203-sup-0001){ref-type="supplementary-material"}0.45% SnF~2~ 0.51% SnCl~2~ 0.53% Zn citrate2013Nevada, USABleeding sites MGIBS: ≥5 MGI: 1.75 to 2.3Negative, SMFP12 weeks10065%41.6 (14.12)Garcia‐Godoy, Duque, Rothrock, Anastasia, & Gerlach, [2015](#jcpe13203-bib-0015){ref-type="ref"}, Summary [S6](#jcpe13203-sup-0001){ref-type="supplementary-material"}0.45% SnF~2~ 2.5% Zn lactate2012Florida, USABleeding sites LSGIMild‐to‐moderate gingivitisNegative, SMFP4 weeks5765%29.1 (8.68)Gerlach & Amini, [2012](#jcpe13203-bib-0016){ref-type="ref"}0.45% SnF~2~ 0.46% SnCl~2~ 1.9% Zn lactate2009Nevada, USABleeding sites MGIBS: n/a MGI: 1.75 to 2.3Negative, SMFP12 weeks10060%33.6 (11.14)Gerlach, Sagel, Winston, Garcia‐Godoy, & Garcia‐Godoy, [2016](#jcpe13203-bib-0017){ref-type="ref"}, Summary [S7](#jcpe13203-sup-0001){ref-type="supplementary-material"}0.45% SnF~2~ 2.5% Zn lactate2007Florida, USATMQHIAdults with plaque and gingivitisSMFP11 weeks9176%33.4 (11.19)Mallatt et al., [2007](#jcpe13203-bib-0040){ref-type="ref"}0.45% SnF~2~ 2.5% Zn lactate2003Florida, USABleeding sites MGIMGI: 1.75 to 2.3Negative, SMFP12 weeks14062%37.7 (11.66)Mankodi et al., [2005](#jcpe13203-bib-0041){ref-type="ref"}0.45% SnF~2~ 2.5% Zn lactate2002Florida, USABleeding sites MGIMGI: 1.75 to 2.3Negative, SMFP12 weeks14367%37.2 (10.87)McClanahan et al., [1997](#jcpe13203-bib-0043){ref-type="ref"}0.45% SnF~2~ 1.5% SnCl~2~1992Indiana, USABleeding sites LSGIBS: \>5Negative, NaF12 weeks38367%35.9 (11.35)Beiswanger et al., [1995](#jcpe13203-bib-0008){ref-type="ref"}0.45% SnF~2~ 1.5% SnCl~2~1988Indiana, USABleeding sites LSGIBS: \>5Negative, SMFP12 weeks46369%33.2 (9.76)

Abbreviations: BS, bleeding sites; LSGI, Löe--Silness Gingival Index; MGI, Modified Gingival Index; N, number of randomized subjects; NaF, sodium fluoride; SMFP, sodium monofluorophosphate; TMQHI, Turesky\'s modification of Quigley--Hein index.

STUDIES IN FIGURE [1](#jcpe13203-fig-0001){ref-type="fig"}B. {#jcpe13203-sec-0118}
============================================================

Study reference or Investigator, YearFormulaYear Study initiatedLocationMeasures & inclusion criteriaControlLength of measurement*N*FemaleMean age in years (*SD*)He, Eusebio, Goyal, & Qaqish, [2017](#jcpe13203-bib-0029){ref-type="ref"}0.45% SnF~2~ 0.51% SnCl~2~ 0.53% Zn citrate2016Ontario, CanadaBleeding sites MGIBS: 10 to 50 MGI: 1.75 to 2.3Positive, NaF/triclosan8 weeks20073%47.9 (10.63)He, Barker, Biesbrock, Miner, et al., [2013](#jcpe13203-bib-0026){ref-type="ref"}0.45% SnF~2~ 0.46% SnCl~2~ 1.9% Zn lactate2011Nevada, USABleeding sites MGIBS: ≥5 MGI: 1.75 to 2.3Positive, NaF/triclosan8 weeks15063%37.4 (11.48)He, Barker, Biesbrock, et al., [2012](#jcpe13203-bib-0027){ref-type="ref"}0.45% SnF~2~ 0.46% SnCl~2~ 1.9% Zn lactate2011Ontario, CanadaBleeding sites MGIBS: ≥5 MGI: 1.75 to 2.3Positive, NaF/triclosan8 weeks15060%42.4 (10.61)He, Barker, Goyal, & Biesbrock, [2012](#jcpe13203-bib-0028){ref-type="ref"}0.45% SnF~2~ 0.46% SnCl~2~ 1.9% Zn lactate2010Nevada, USABleeding sites MGIBS: ≥5 MGI: 1.75 to 2.3Positive, NaF/triclosan8 weeks20061%38.1 (13.28)Mankodi, 2009 Unpublished, Summary [S8](#jcpe13203-sup-0001){ref-type="supplementary-material"}0.45% SnF~2~ 0.46% SnCl~2~ 1.9% Zn lactate2009Florida, USABleeding sites MGIBS: n/a MGI: 1.75 to 2.3Positive, NaF/triclosan12 weeks20570%42.1 (12.91)Archila et al., [2005](#jcpe13203-bib-0004){ref-type="ref"}0.45% SnF~2~ 2.5% Zn lactate2002GuatemalaBleeding sites LSGIMild‐to‐moderate gingivitisPositive, NaF/triclosan12 weeks19776%29.8 (9.42)McClanahan et al., [1997](#jcpe13203-bib-0043){ref-type="ref"}0.45% SnF~2~ 1.5% SnCl~2~1992Indiana, USABleeding sites LSGIBS: \>5 LSGI: n/aPositive, NaF/triclosan12 weeks35967%36.1 (11.11)

Abbreviations: BS, bleeding sites; LSGI, Löe--Silness Gingival Index; MGI, Modified Gingival Index; N, number of randomized subjects; NaF, sodium fluoride; SMFP, sodium monofluorophosphate.
